AstraZeneca Industries

As of December 2020, the main activity is the production of drugs and materials used for medical purposes.

Performance indicators

2024: Revenue growth 1.5 times to ₽37,79 billion

The revenue of AstraZeneca Industries LLC, the Russian division of the biopharmaceutical company AstraZeneca, increased 1.5 times in 2024 and reached ₽37,79 billion. The growth of the financial indicator is due to the expansion of production activities and an increase in the volume of supplies. The company's net profit also grew 1.5 times, amounting to ₽3,7 billion according to reports published in early April 2025.

According to Interfax, according to the company's report, this is the maximum net profit since 2015, when the plant was launched in the Kaluga region. The cost of sales increased commensurate with the revenue - 1.47 times, reaching ₽29,6 billion.

𝓲

Фото: seekingalpha.com

The gross profit of the enterprise increased 1.54 times - up to ₽8,2 billion. Profit from sales showed the most significant growth - 1.65 times and amounted to ₽7,17 billion. Profit before tax increased 1.52 times and reached ₽4,85 billion.

The financial position of the company is characterized by a reduction in accounts payable from ₽19,52 billion at the beginning of 2024 to ₽18,93 billion at the end of the year. At the same time, receivables increased from ₽20,38 billion to ₽26,81 billion over the same period.

The AstraZeneca Industries plant is located in the Vorsino Industrial Park of the Kaluga Region and has a production capacity of 40 million packages, or 850 million tablets per year. The company was put into operation in October 2015, and the total investment in the project exceeded $224 million. Commercial production began in 2016.^[1]

2022: Revenue growth to a new record of 23.61 billion rubles, profit - up to 2.18 billion rubles

In 2022, AstraZeneca Industries LLC received revenue of 23.61 billion rubles against 14.92 billion rubles a year earlier. The net profit of the Russian plant of the Swedish-British biopharmaceutical company AstraZeneca in comparison with these periods rose by 36.7% - from 1.59 billion to 2.18 billion rubles. Such data were released at the end of April 2023.

According to Interfax, citing materials from AstraZeneca Industries LLC, the company's revenue in 2022 was a record, and net profit was the second largest in history. The maximum profit was dated 2020, when it amounted to 2.99 billion rubles.

AstraZeneca Industries LLC Vorsino Plant

The company's accounts payable in 2022 reached 11.24 billion rubles against 6.92 billion rubles a year earlier, receivables - 13.77 billion rubles against 10.42 billion rubles in 2021.

The AstraZeneca Industries LLC plant in Vorsino (Kaluga Region) has a capacity of 40 million packages, or 850 million tablets per year (data at the end of December 2022).

In 2022, AstraZeneca continued to work in Russia, despite the fact that a large number of foreign companies left the market after the start of a special operation of the Russian Federation in Ukraine.

AstraZeneca continues to operate in Russia and is taking all necessary measures to ensure uninterrupted supplies of medicines, as well as continuous production at the company's plant in the Kaluga region, the manufacturer said in a statement.

The company also noted that it is doing everything possible to support ongoing projects, including providing patients with medicines, their production, scientific and educational activities and clinical research. AstraZeneca has been present on the Russian market since 1993.^[2]

Notes